Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

T. Flaherty, Keith; Infante, J.; Daud, Adil; González, René; Kefford, Richard; A. Sosman, Jeffrey; Hamid, Omid; M. Schuchter, Lynn; Cebon, Jonathan; Ibrahim, Nageatte; R. Kudchadkar, Ragini; A. Burris, Howard; S. Falchook, Gerald; P. Algazi, Alain; D. Lewis, Karl; V. Long, Georgina; Puzanov, Igor; F. Lebowitz, Peter; P. Singh, Ajay; M Little, Shonda; Sun, Peng; J. Allred, Alicia; Ouellet, Danièle; B. Kim, Kevin; Patel, Kiran; S. Weber, Jeffrey

doi:10.1056/nejmoa1210093

Public

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

Published in New England Journal of Medicine • Sep 30, 2012

Authors:

Keith T. Flaherty

J. Infante

Adil Daud

Abstract

BACKGROUND: Resistance to therapy with BRAF kinase inhibitors is associated with reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selec...

Subject

Trametinib

Dabrafenib

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!